The role of metalloproteases inLeishmaniaspecies infection in the New World: a systematic review

Parasitology ◽  
2018 ◽  
Vol 145 (12) ◽  
pp. 1499-1509 ◽  
Author(s):  
Letícia Sayuri Murase ◽  
João Vítor Perez de Souza ◽  
Quirino Alves de Lima Neto ◽  
Tatiane França Perles de Mello ◽  
Bruna Muller Cardoso ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cutaneous Leishmaniasis ◽  
New World ◽  
Leishmania Species ◽  
Matrix Metalloproteases ◽  
Response To Treatment ◽  
Immune Functions ◽  
Host Matrix ◽  
Tissue Levels

AbstractThis is a systematic review on the role of metalloproteases in the pathogenicity of the American tegumentary leishmaniasis (ATL) caused by New World Leishmania species. The review followed the PRISMA method, searching for articles in PubMed, EMBASE, LILACS and ISI Web of Science, by employing the following terms: ‘leishmaniasis’, ‘cutaneous leishmaniasis’, ‘mucocutaneous leishmaniasis’, ‘diffuse cutaneous leishmaniasis’, ‘Leishmania’ and ‘metalloproteases’. GP63 of New WorldLeishmaniaspecies is a parasite metalloproteases involved in the degradation and cleavage of many biological molecules as kappa-B nuclear factor, fibronectin, tyrosine phosphatases. GP63 is capable of inhibiting the activity of the complement system and reduces the host's immune functions, allowing the survival of the parasite and its dissemination. High serological/tissue levels of host matrix metalloproteases (MMP)-9 have been associated with tissue damage during the infection, while high transcriptional levels of MMP-2 related with a satisfactory response to treatment. Host MMPs serological and tissue levels have been investigated using Western Blot, zymography, and Real Time polymerase chain reaction. GP63 detection characterizes species and virulence in promastigotes isolated from lesions samples using techniques mentioned previously. The monitoring of host MMPs levels and GP63 in Leishmania isolated from host samples could be used on the laboratory routine to predict the prognostic and treatment efficacy of ATL.

The Role of CD1a expression in the diagnosis of cutaneous leishmaniasis, its relationship with Leishmania species and clinicopathological features

2021 ◽  
Author(s):  
Yasemin Yuyucu Karabulut ◽  
Funda KuŞ Bozkurt ◽  
Ümit Türsen ◽  
Gül Bayram ◽  
Gülhan Örekeci Temel ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Leishmania Species ◽  
Clinicopathological Features

scholarly journals Molecular Identification of Species Caused Cutaneous Leishmaniasis in Southern Zone of Iran

2019 ◽  
Author(s):  
Afshin Barazesh ◽  
Mohammad Hossein Motazedian ◽  
Moradali Fouladvand ◽  
Gholamreza Hatam ◽  
Saeed Tajbakhsh ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Leishmania Major ◽  
Synergistic Effects ◽  
Leishmania Species ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Skin Ulcers ◽  
Identification Of Species ◽  
Main Factor

Background: Leishmania major and Leishmania tropica are two main species causing cutaneous leishmaniasis (CL) in Iran. Recently, Crithidia spp. has also been reported in the wound of patients with CL. In this study, we determined the species causing CL in the southern of Iran and the role of Crithidia spp. in creating skin ulcers. Methods: In this cross-sectional study from Apr to Sep 2016, 66 patients with CL referred to Diagnostic Lab of Leishmaniasis, Valfajr Health Center, Shiraz, Iran, were selected. After DNA extraction from the Giemsa stained smears, all samples were amplified in two separate steps using specific primers, firstly, to differentiate Leishmania species and then to identify Crithidia spp. Results: Two species L. major and L. tropica were responsible for 60 and 6 cases, respectively. Moreover, in two patients, mixed infection with Crithidia was confirmed. In mix infection cases, the morphology of the cutaneous ul­cers was not different from the wounds of other patients. Conclusion: Leishmania major is responsible for the most common CL in southern Iran. In addition, in two patients with L. major and L. tropica, mix infection with Crithidia was confirmed. The potential role of Crithidia as the main factor for CL and the probability of this parasite to have synergistic effects on Leishmania, as a hypothesis, requires more comprehensive researches on the ambiguity of this protozoon.

In vitro activity and in vivo efficacy of fexinidazole against New World Leishmania species

2019 ◽  
Vol 74 (8) ◽  
pp. 2318-2325 ◽  
Author(s):  
Eliane de Morais-Teixeira ◽  
Ana Rabello ◽  
Marta Marques Gontijo Aguiar
Keyword(s):  
Cutaneous Leishmaniasis ◽  
New World ◽  
Leishmania Species ◽  
Vitro Activity ◽  
In Vitro Assays ◽  
In Vitro Activity ◽  
In Vivo Evaluation ◽  
In Vivo Efficacy

Abstract Objectives To evaluate the in vitro activity and in vivo efficacy of fexinidazole against the main species that cause visceral and cutaneous New World leishmaniasis. Methods The inhibitory concentrations of fexinidazole against Leishmania (Leishmania) infantum chagasi, Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis in amastigotes were determined by in vitro activity assays. For the in vivo evaluation, animals were infected with L. (L.) infantum chagasi, L. (L.) amazonensis, L. (V.) braziliensis or Leishmania (Viannia) guyanensis and divided into groups: (i) control; and (ii) treated with oral fexinidazole, from 50 to 300 mg/kg/day. For cutaneous leishmaniasis, the size of the lesion was determined weekly after the beginning of the treatment. Upon completion, parasites were recovered from the spleen and liver, or skin lesion and spleen, and evaluated by a limiting dilution assay. Results All Leishmania isolates were susceptible to fexinidazole in the in vitro assays. The viable parasites in the liver and spleen were reduced with 100 and 300 mg/kg/day, respectively, for L. (L.) infantum chagasi. For the species causing cutaneous leishmaniasis, the viable parasites in lesions and the size of the lesions were reduced, starting from 200 mg/kg/day. The viable parasites in the spleen were also reduced with 200 and 300 mg/kg/day for L. (V.) braziliensis and L. (L.) amazonensis. Conclusions Considering the defined parameters, fexinidazole showed in vitro and in vivo activity against all tested species. This drug may represent an alternative treatment for the New World species.

scholarly journals The Role of Non-Gaussian Models of Diffusion Weighted MRI in Hepatocellular Carcinoma: A Systematic Review

2021 ◽  
Vol 10 (12) ◽  
pp. 2641
Author(s):  
Liberatore Tramontano ◽  
Carlo Cavaliere ◽  
Marco Salvatore ◽  
Valentina Brancato
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Current Knowledge ◽  
Exponential Model ◽  
Response To Treatment ◽  
Diffusion Kurtosis Imaging ◽  
Diffusion Weighted ◽  
Non Gaussian ◽  
Diffusion Kurtosis

The importance of Diffusion Weighted Imaging (DWI) in hepatocellular carcinoma (HCC) has been widely handled in the literature. Due to the mono-exponential model limitations, several studies recently investigated the role of non-Gaussian DWI models in HCC. However, their results are variable and inconsistent. Therefore, the aim of this systematic review is to summarize current knowledge on non-Gaussian DWI techniques in HCC. A systematic search of the literature, including PubMed, Google Scholar, MEDLINE, and ScienceDirect databases, was performed to identify original articles since 2010 that evaluated the role of non-Gaussian DWI models for HCC diagnosis, grading, response to treatment, and prognosis. Studies were grouped and summarized according to the non-Gaussian DWI models investigated. We focused on the most used non-Gaussian DWI models (Intravoxel Incoherent Motion (IVIM), Diffusion Kurtosis Imaging (DKI), and Stretched Exponential—SE). The quality of included studies was evaluated by using QUADAS-2 and QUIPS tools. Forty-three articles were included, with IVIM and DKI being the most investigated models. Although the role of non-Gaussian DWI models in clinical settings has not fully been established, our findings showed that their parameters may potentially play a role in HCC. Further studies are required to identify a standardized DWI acquisition protocol for HCC diagnosis, grading, response to treatment, and prognosis.

scholarly journals Molecular Characterisation of Leishmania Species from Stray Dogs and Patients in Saudi Arabia

2020 ◽  
Author(s):  
Abdullah D Alanazi ◽  
Abdulazi S Alouffi ◽  
Mohamed S Alyousif ◽  
Abdulsadah A Rahi ◽  
Magda A Ali ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Cutaneous Leishmaniasis ◽  
Leishmania Major ◽  
Leishmania Species ◽  
Sand Fly ◽  
Human Populations ◽  
Nested Polymerase Chain Reaction ◽  
Stray Dogs ◽  
Control And Prevention

Abstract Background: Leishmania major and Leishmania tropica cause cutaneous leishmaniasis in humans and dogs in several parts of the world, with a large number of cases recorded in the Middle East. However, when they occur in sympatry, the role of each species of Leishmania in the epidemiology of cutaneous leishmaniasis (CL) is not clear. Methods: To determine the frequency of occurrence and to identify the species of Leishmania that infect humans and stray dogs in Riyadh and Al-Qaseem (Saudi Arabia), 311 stray dogs and 27 human patients who were suspected for Leishmania were examined for CL by a nested polymerase chain reaction (nPCR).Results: The use of nPCR detected seven patients (25.9%) who were positive for cutaneous leishmaniasis. Five patients from Riyadh were infected by L. major and two from Al-Qaseem by L. tropica. In addition, five dogs (1.6%) were infected by L. tropica. Conclusions: This is one of the first molecular studies of leishmaniasis to be conducted in Saudi Arabia. The relationship between the sand-fly vectors and the reservoirs of both Leishmania spp. is still scarcely known in this region, and epidemiological investigations are required in order to progress towards control and prevention of the infection in canine and human populations.

scholarly journals SP5-33 Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the new world

2011 ◽  
Vol 65 (Suppl 1) ◽  
pp. A454-A454 ◽  
Author(s):  
L. Oliveira ◽  
A. Schubach ◽  
M. Martins ◽  
S. Passos ◽  
R. Oliveira ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Effects ◽  
Cutaneous Leishmaniasis ◽  
New World

scholarly journals A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Katie Bechman ◽  
Anthony Dalrymple ◽  
Charles Southey-Bassols ◽  
Andrew P. Cope ◽  
James B. Galloway
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Disease Activity ◽  
Treatment Response ◽  
Janus Kinase ◽  
Response To Treatment ◽  
Healthy Controls ◽  
Treatment Prediction ◽  
Randomised Controlled

Abstract Background The B cell chemoattractant CXCL13 is a promising biomarker in rheumatoid arthritis (RA), with a plausible role in supporting diagnosis, monitoring disease activity and as a prognostic value. It is a key chemokine driving the formation of lymphoid follicles within the inflamed synovium. The objective of this systematic review was to evaluate the role of CXCL13 as a viable biomarker in RA. Methods We conducted a systematic literature review of all published cohort and randomised controlled trials evaluating the role of CXCL13 in RA. The primary outcomes were; i) CXCL13 levels in RA patients compared to healthy controls, ii) the correlation between CXCL13 and markers of disease activity, and iii) the association between CXCL13 and treatment response. Results The search produced 278 articles, of which 31 met the inclusion criteria. Of the 12 studies evaluating CXCL13 expression in early or established RA, all reported higher levels than that seen in healthy controls. Twelve of sixteen studies reported a weakly positive correlation between CXCL13 and markers of disease activity including DAS28 and swollen joint count, with rho values between 0.20–0.67. In 2 studies, CXCL13 levels correlated with ultrasonographic evidence of synovitis. Eighteen studies assessed CXCL13 in response to therapeutic intervention. The majority signified a fall in levels in response to treatment including biologics and Janus kinase (JAK) inhibition. In some, this reduction was only seen in treatment responders. High CXCL13 levels predicted failure to achieve disease remission with csDMARDs. The evidence for treatment prediction with biologics was conflicting. Conclusion Despite evidence to suggest a role in diagnosing RA and in detecting synovitis, the heterogeneity of studies included in this review limit our ability to draw robust conclusions. At present there are inadequate results to justify the routine use of CXCL13 as a biomarker in RA routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document